OLUX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OLUX (OLUX).
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Topical administration; minimal systemic absorption. Absorbed fraction is metabolized in the liver via CYP3A4. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites; less than 1% of the applied dose is excreted unchanged in urine. In fecal elimination, approximately 0.5-2% is recovered after topical application. |
| Half-life | The terminal elimination half-life is approximately 3 hours for clobetasol propionate following topical application. This short half-life supports once- to twice-daily dosing for efficacy while minimizing systemic accumulation. |
| Protein binding | Clobetasol propionate is approximately 96-98% bound to plasma proteins, predominantly albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | The apparent volume of distribution (Vd/F) for clobetasol propionate after topical application is difficult to determine accurately due to limited systemic absorption. In systemic studies with intravenous administration, Vd is estimated to be 1-2 L/kg, indicating extensive tissue distribution. After topical application, the Vd is not clinically meaningful due to negligible systemic levels. |
| Bioavailability | Bioavailability after topical application is less than 1% of the applied dose; systemic absorption is minimal and dependent on skin integrity, vehicle, and site of application. Oral bioavailability is negligible due to extensive first-pass metabolism. The product is intended for topical use only. |
| Onset of Action | Onset of action for OLUX (clobetasol propionate) foam is rapid; clinical improvement (reduction in erythema, scaling, and pruritus) is typically observed within 1 week of twice-daily application. For the ointment and cream formulations, onset is also within several days to 1 week. |
| Duration of Action | Duration of action after a single application is approximately 12-24 hours, consistent with twice-daily dosing recommendations. With continued use, clinical effects are maintained; prolonged use (beyond 2 weeks) is discouraged due to risk of local and systemic adverse effects. |
| Molecular Weight | 466.96 |
Olux (clobetasol propionate) is a topical corticosteroid. Apply a thin layer to affected skin areas twice daily. Maximum adult dose: 50 g (or 50 mL) per week. Treatment duration should not exceed 2 consecutive weeks. Not for use on face, groin, or axillae.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended due to potential for significant systemic absorption and adrenal suppression. For children aged 12 years and older, apply a thin layer to affected area once or twice daily for up to 2 weeks; maximum dose: 25 g per week. |
| Geriatric use | No specific dose adjustment in elderly. Use with caution due to increased risk of skin atrophy and systemic effects; apply the shortest duration and smallest amount necessary. |
| 1st trimester | Clobetasol propionate is a super-high potency corticosteroid. Topical use during the first trimester should be avoided unless absolutely necessary; limited data suggest no major increased risk of malformations with topical corticosteroids, but systemic absorption can occur. |
| 2nd trimester | Use only if clearly needed and with caution; avoid prolonged use, large areas, or occlusive dressings. Potential for fetal growth restriction and adrenal suppression with significant systemic absorption. |
| 3rd trimester | Avoid use near term if possible; topical corticosteroids may cause neonatal adrenal suppression if used heavily. Short-term, limited-area use may be acceptable under medical supervision. |
Clinical note
Comprehensive clinical and safety monograph for OLUX (OLUX).
| Placental transfer | Clobetasol propionate is a corticosteroid; systemic absorption after topical application is low (approximately 1-5% of dose). However, with extensive or occlusive use, systemic levels may be sufficient to cross the placenta. Distribution is rapid once in systemic circulation. |
■ FDA Black Box Warning
None
| Serious Effects |
Untreated bacterial, fungal, or viral skin infectionsPerioral dermatitisRosaceaHypersensitivity to clobetasol propionate or any component of the formulation
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Local adverse reactions including skin atrophy, striae, telangiectasias, and acneiform eruptions, Avoid use on face, groin, or axillae due to increased risk of atrophy, Do not use with occlusive dressings unless directed, Pediatric patients may be more susceptible to systemic toxicity |
| Food/Dietary | No food interactions known. Take with or without food. |
Loading safety data…
| Breastfeeding |
| Topical application to the breast should be avoided before nursing to prevent infant ingestion. Use the smallest amount for the shortest duration. Systemic absorption is low with intact skin, but caution is advised with prolonged use or if applied to large areas/denuded skin. |
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Pregnancy category C. Topical corticosteroids have been associated with fetal growth restriction and adrenal suppression when used systemically. First trimester: limited data, theoretical risk of cleft palate with prolonged use. Second/third trimesters: risk of intrauterine growth restriction (IUGR) and low birth weight with extensive or prolonged use. Avoid use in large amounts or occluded areas. Use lowest effective dose for shortest duration. |
| Fetal Monitoring | Monitor fetal growth via ultrasound if prolonged use or large body surface area (>10%) to assess for IUGR. Assess maternal adrenal function if signs of Cushing syndrome. Monitor infant for adrenal suppression if maternal use was extensive near term. |
| Fertility Effects | No specific data on human fertility effects. Animal studies show no impairment of fertility with topical corticosteroids at therapeutic doses. Unlikely to affect fertility due to minimal systemic absorption. |
| Clinical Pearls |
| OLUX (clobetasol propionate) is a super-high potency topical corticosteroid. Limit use to 2 consecutive weeks due to risk of HPA axis suppression. Do not use on face, groin, or axillae. Apply sparingly; 50 g per week total should not be exceeded to minimize systemic absorption. |
| Patient Advice | Apply a thin layer to affected skin only, avoiding healthy skin. · Do not use for more than 2 weeks continuously. · Avoid covering treated areas with bandages unless directed. · Do not use on face, underarms, or groin. · Wash hands after application unless hands are being treated. · Do not use for any other condition without consulting your doctor. · Inform your doctor if you experience vision changes, skin thinning, or signs of infection. |